Sulfonyl fluoride inhibitors of fatty acid amide hydrolase

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 10074-10089

  Alapafuja, Shakiru O ^b   Nikas, Spyros P ^a   Bharathan, Indu T ^a   Shukla, Vidyanand G ^a   Nasr, Mahmoud L ^a   Bowman, Anna L ^a   Zvonok, Nikolai ^a   Li, Jing ^a   Shi, Xiaomeng ^a   Engen, John R ^a   Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MAK Scientific LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLPROPANE 1 SULFONYL FLUORIDE; 4 PHENYLBUTANE 1 SULFONYL FLUORIDE; 5 (4 BENZYLOXYPHENYL)PENTANESULFONYL FLUORIDE; 5 (4 HYDROXYPHENYL)PENTANESULFONYL FLUORIDE; 5 PHENYLPENTANE 1 SULFONYL FLUORIDE; 6 PHENYLHEXANE 1 SULFONYL FLUORIDE; 7 (2 BENZYLOXYPHENYL)HEPTANESULFONYL FLUORIDE; 7 (2 HYDROXYPHENYL)HEPTANESULFONYL FLUORIDE; 7 (3 BENZYLOXYPHENYL)HEPTANESULFONYL FLUORIDE; 7 (3 HYDROXYPHENYL)HEPTANESULFONYL FLUORIDE; 7 (4 BENZYLOXYPHENYL)HEPTANESULFONYL FLUORIDE; 7 (4 HYDROXYPHENYL)HEPTANESULFONYL FLUORIDE; 7 PHENYLHEPTANE 1 SULFONYL FLUORIDE; 8 PHENYLOCTANE 1 SULFONYL FLUORIDE; AM 3506; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MASS SPECTROMETRY; MOLECULAR DOCKING; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALKANESULFONATES; AMIDOHYDROLASES; ANIMALS; BRAIN; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PALMITATES; PHENOLS; RADIOLIGAND ASSAY; RATS; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870020101     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301205j     Document Type: Article

References (71)

1. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 1996, 384, 83-87
2. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 2002, 298, 1793-1796
3. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949
4. Devane, W. A.; Dysarz, F. A., 3rd; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 1988, 34, 605-613
5. Cravatt, B. F.; Prospero-Garcia, O.; Siuzdak, G.; Gilula, N. B.; Henriksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical characterization of a family of brain lipids that induce sleep Science 1995, 268, 1506-1509
6. Boger, D. L.; Patterson, J. E.; Jin, Q. Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 4102-4107
7. Yost, C. S.; Hampson, A. J.; Leonoudakis, D.; Koblin, D. D.; Bornheim, L. M.; Gray, A. T. Oleamide potentiates benzodiazepine-sensitive gamma-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration Anesth. Analg. 1998, 86, 1294-1300
8. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 9371-9376
9. Hwang, J.; Adamson, C.; Butler, D.; Janero, D. R.; Makriyannis, A.; Bahr, B. A. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality Life Sci. 2010, 86, 615-623
10. Ahn, K.; Johnson, D. S.; Cravatt, B. F. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Expert Opin. Drug Discovery 2009, 4, 763-784
11. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids Nature 1998, 394, 277-281
12. Ligresti, A.; Bisogno, T.; Matias, I.; De Petrocellis, L.; Cascio, M. G.; Cosenza, V.; D'Argenio, G.; Scaglione, G.; Bifulco, M.; Sorrentini, I.; Di Marzo, V. Possible endocannabinoid control of colorectal cancer growth Gastroenterology 2003, 125, 677-687
13. Melck, D.; Rueda, D.; Galve-Roperh, I.; De Petrocellis, L.; Guzman, M.; Di Marzo, V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells FEBS Lett. 1999, 463, 235-240
14. Mimeault, M.; Pommery, N.; Wattez, N.; Bailly, C.; Henichart, J. P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production Prostate 2003, 56, 1-12
15. Castellano, C.; Cabib, S.; Palmisano, A.; Di Marzo, V.; Puglisi-Allegra, S. The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors Behav. Pharmacol. 1997, 8, 707-712
16. Mallet, P. E.; Beninger, R. J. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta-9- tetrahydrocannabinol or anandamide Psychopharmacology (Berlin) 1998, 140, 11-19
17. Naidoo, V.; Nikas, S. P.; Karanian, D. A.; Hwang, J.; Zhao, J.; Wood, J. T.; Alapafuja, S. O.; Vadivel, S. K.; Butler, D.; Makriyannis, A.; Bahr, B. A. A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity J. Mol. Neurosci. 2011, 43, 493-502
18. Karanian, D. A.; Karim, S. L.; Wood, J. T.; Williams, J. S.; Lin, S.; Makriyannis, A.; Bahr, B. A. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage J. Pharmacol. Exp. Ther. 2007, 322, 1059-1066
19. Karanian, D. A.; Brown, Q. B.; Makriyannis, A.; Kosten, T. A.; Bahr, B. A. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity J. Neurosci. 2005, 25, 7813-7820
20. Wallace, M. J.; Martin, B. R.; DeLorenzo, R. J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity Eur. J. Pharmacol. 2002, 452, 295-301
21. Gomez, R.; Navarro, M.; Ferrer, B.; Trigo, J. M.; Bilbao, A.; Del Arco, I.; Cippitelli, A.; Nava, F.; Piomelli, D.; Rodriguez de Fonseca, F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding J. Neurosci. 2002, 22, 9612-9617
22. Milton, N. G. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide Neurosci. Lett. 2002, 332, 127-130
23. Gobbi, G.; Bambico, F. R.; Mangieri, R.; Bortolato, M.; Campolongo, P.; Solinas, M.; Cassano, T.; Morgese, M. G.; Debonnel, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Mor, M.; Trezza, V.; Goldberg, S. R.; Cuomo, V.; Piomelli, D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 18620-18625
24. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 2003, 9, 76-81
25. Godlewski, G.; Alapafuja, S. O.; Batkai, S.; Nikas, S. P.; Cinar, R.; Offertaler, L.; Osei-Hyiaman, D.; Liu, J.; Mukhopadhyay, B.; Harvey-White, J.; Tam, J.; Pacak, K.; Blankman, J. L.; Cravatt, B. F.; Makriyannis, A.; Kunos, G. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects Chem. Biol. (Cambridge, MA, U. S.) 2010, 17, 1256-1266
26. Bashashati, M.; Storr, M. A.; Nikas, S. P.; Wood, J. T.; Godlewski, G.; Liu, J.; Ho, W.; Keenan, C. M.; Zhang, H.; Alapafuja, S. O.; Cravatt, B. F.; Lutz, B.; Mackie, K.; Kunos, G.; Patel, K. D.; Makriyannis, A.; Davison, J. S.; Sharkey, K. A. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice Br. J. Pharmacol. 2012, 165, 1556-1571
27. Fowler, C. J.; Holt, S.; Nilsson, O.; Jonsson, K. O.; Tiger, G.; Jacobsson, S. O. The endocannabinoid signaling system: pharmacological and therapeutic aspects Pharmacol., Biochem. Behav. 2005, 81, 248-262
28. Minkkila, A.; Saario, S.; Nevalainen, T. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors Curr. Top. Med. Chem. 2010, 10, 828-858
29. Deutsch, D. G.; Lin, S.; Hill, W. A.; Morse, K. L.; Salehani, D.; Arreaza, G.; Omeir, R. L.; Makriyannis, A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor Biochem. Biophys. Res. Commun. 1997, 231, 217-221
30. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J. Med. Chem. 2003, 46, 2352-2360
31. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies J. Med. Chem. 2004, 47, 4998-5008
32. Johnson, D. S.; Stiff, C.; Lazerwith, S. E.; Kesten, S. R.; Fay, L. K.; Morris, M.; Beidler, D.; Liimatta, M. B.; Smith, S. E.; Dudley, D. T.; Sadagopan, N.; Bhattachar, S. N.; Kesten, S. J.; Nomanbhoy, T. K.; Cravatt, B. F.; Ahn, K. Discovery of PF-04457845: A highly potent, orally bioavailable, and selective urea FAAH inhibitor ACS Med. Chem. Lett. 2011, 2, 91-96
33. Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition Bioorg. Med. Chem. Lett. 1999, 9, 265-270
34. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaraes, C. R.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics J. Med. Chem. 2005, 48, 1849-1856
35. Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apodaca, R. L.; Breitenbucher, J. G.; Cravatt, B. F.; Boger, D. L. Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase J. Med. Chem. 2007, 50, 1058-1068
36. Kimball, F. S.; Romero, F. A.; Ezzili, C.; Garfunkle, J.; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase J. Med. Chem. 2008, 51, 937-947
37. Feledziak, M.; Michaux, C.; Urbach, A.; Labar, G.; Muccioli, G. G.; Lambert, D. M.; Marchand-Brynaert, J. beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase J. Med. Chem. 2009, 52, 7054-7068
38. Muccioli, G. G.; Fazio, N.; Scriba, G. K.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. Substituted 2-thioxoimidazolidin-4- ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates J. Med. Chem. 2006, 49, 417-425
39. Alapafuja, S. O.; Nikas, S. P.; Shukla, V. G.; Papanastasiou, I.; Makriyannis, A. Microwave assisted synthesis of sodium sulfonates precursors of sulfonyl chlorides and fluorides Tetrahedron Lett. 2009, 50, 7028-7031
40. Gunduz-Cinar, O.; MacPherson, K. P.; Cinar, R.; Gamble-George, J.; Sugden, K.; Williams, B.; Ramikie, T. S.; Gorka, A. X.; Alapafuja, S. O.; Nikas, S. P.; Makriyannis, A.; Poulton, R.; Patel, S.; Hariri, A. R.; Caspi, A.; Moffitt, T. E.; Kunos, G.; Holmes, A. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 2012, [Online early access] DOI: 10.1038/mp.2012.1072. Published Online: June 1012, 2012.
41. Makriyannis, A.; Nikas, S. P.; Alapafuja, S. O.; Shukla, V. G. Fatty acid amide hydrolase inhibitors. WO Patent Application 2008/013963 A2, University of Connecticut, 2008; 123 pp.
42. Makriyannis, A.; Nikas, S. P.; Alapafuja, S. O.; Shukla, V. G. Monoacylgylcerol lipase inhibitors for modulation of cannabinoid activity. WO Patent Application 2009/052319 A1, Northeastern University: 2009; 209 pp.
43. Makriyannis, A.; Pandarinathan, L.; Zvonok, N.; Parkkari, T.; Chapman, L. Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors. WO Patent Application 2009/117444 A1, Northeastern University, 2009; 109 pp.
44. Naidoo, V.; Karanian, D. A.; Vadivel, S. K.; Locklear, J. R.; Wood, J. T.; Nasr, M.; Quizon, P. M.; Graves, E. E.; Shukla, V.; Makriyannis, A.; Bahr, B. A. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase-dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics 2012, [Online early access] DOI: 10.1007/S13311-13011-10100-y. Published Online: Jannuary 13, 2012.
45. Zvonok, N.; Pandarinathan, L.; Williams, J.; Johnston, M.; Karageorgos, I.; Janero, D. R.; Krishnan, S. C.; Makriyannis, A. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis Chem. Biol. 2008, 15, 854-862
46. Zvonok, N.; Williams, J.; Johnston, M.; Pandarinathan, L.; Janero, D. R.; Li, J.; Krishnan, S. C.; Makriyannis, A. Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification J. Proteome Res. 2008, 7, 2158-2164
47. Nikas, S. P.; Grzybowska, J.; Papahatjis, D. P.; Charalambous, A.; Banijamali, A. R.; Chari, R.; Fan, P.; Kourouli, T.; Lin, S.; Nitowski, A. J.; Marciniak, G.; Guo, Y.; Li, X.; Wang, C. L.; Makriyannis, A. The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model AAPS J. 2004, 6, e30
48. Bailey, W. F.; Punzalan, E. R. Convenient general method for the preparation of primary alkyllithiums by lithium-iodine exchange J. Org. Chem. 1990, 55, 5400-5406
49. Quast, H.; Kees, F. Alkansulfonyl-chloride aus alkyllithium und sulforylchlorid Synthesis 1974, 7, 489-490
50. Papahatjis, D. P.; Nahmias, V. R.; Nikas, S. P.; Andreou, T.; Alapafuja, S. O.; Tsotinis, A.; Guo, J.; Fan, P.; Makriyannis, A. C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols J. Med. Chem. 2007, 50, 4048-4060
51. Bhatt, M. V.; Kulkarni, S. U. Cleavage of ethers Synthesis - Stuttgart 1983, 249-282
52. Ramarao, M. K.; Murphy, E. A.; Shen, M. W.; Wang, Y.; Bushell, K. N.; Huang, N.; Pan, N.; Williams, C.; Clark, J. D. A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening Anal. Biochem. 2005, 343, 143-151
53. Patricelli, M. P.; Lashuel, H. A.; Giang, D. K.; Kelly, J. W.; Cravatt, B. F. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization Biochemistry 1998, 37, 15177-15187
54. Mileni, M.; Garfunkle, J.; DeMartino, J. K.; Cravatt, B. F.; Boger, D. L.; Stevens, R. C. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures J. Am. Chem. Soc. 2009, 131, 10497-10506
55. Mileni, M.; Garfunkle, J.; Ezzili, C.; Kimball, F. S.; Cravatt, B. F.; Stevens, R. C.; Boger, D. L. X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase J. Med. Chem. 2010, 53, 230-240
56. Nikas, S. P.; Alapafuja, S. O.; Papanastasiou, I.; Paronis, C. A.; Shukla, V. G.; Papahatjis, D. P.; Bowman, A. L.; Halikhedkar, A.; Han, X.; Makriyannis, A. Novel 1′,1′-chain substituted hexahydrocannabinols: 9beta-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist J. Med. Chem. 2010, 53, 6996-7010
57. Giang, D. K.; Cravatt, B. F. Molecular characterization of human and mouse fatty acid amide hydrolases Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 2238-2242
58. Copeland, R. A., Lead optimization and SAR for reversible inhibitors. In Evaluation of enzyme inhibitors in drug discovery; Copeland, R. A., Ed.; John Wiley and Sons Inc.;: Hoboken, NJ, 2005; pp 125-128.
59. Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Nomanbhoy, T. K.; Alexander, J. P.; Cravatt, B. F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity Biochemistry 2007, 46, 13019-13030
60. Alexander, J. P.; Cravatt, B. F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes Chem. Biol. 2005, 12, 1179-1187
61. Gold, A. M. Sulfonyl fluorides as inhibitors of esterases. 3. Identification of serine as the site of sulfonylation in phenylmethanesulfonyl alpha-chymotrypsin Biochemistry 1965, 4, 897-901
62. Gold, A. M.; Fahrney, D. Sulfonyl fluorides as inhibitors of esterases. Ii. Formation and reactions of phenylmethanesulfonyl alpha-chymotrypsin Biochemistry 1964, 3, 783-791
63. Yoshida, T.; Murai, M.; Abe, M.; Ichimaru, N.; Harada, T.; Nishioka, T.; Miyoshi, H. Crucial structural factors and mode of action of polyene amides as inhibitors for mitochondrial NADH-ubiquinone oxidoreductase (complex I) Biochemistry 2007, 46, 10365-10372
64. Hahn, R. C.; Tompkins, J. One-pot, one- and multi-carbon homologation of alkyl halides: reaction of Grignard reagents with chloroiodomethane Tetrahedron Lett. 1990, 31, 937-940
65. Ichimaru, N.; Murai, M.; Kakutani, N.; Kako, J.; Ishihara, A.; Nakagawa, Y.; Nishioka, T.; Yagi, T.; Miyoshi, H. Synthesis and characterization of new piperazine-type inhibitors for mitochondrial NADH-ubiquinone oxidoreductase (complex I) Biochemistry 2008, 47, 10816-10826
66. Castang, S.; Chantegrel, B.; Deshayes, C.; Dolmazon, R.; Gouet, P.; Haser, R.; Reverchon, S.; Nasser, W.; Hugouvieux-Cotte-Pattat, N.; Doutheau, A. N-Sulfonyl homoserine lactones as antagonists of bacterial quorum sensing Bioorg. Med. Chem. Lett. 2004, 14, 5145-5149
67. McManus, S. P.; Smith, M. R.; Abramovitch, R. A.; Offor, M. N. Thermolysis of sulfonyl azides bearing nucleophilic neighboring groups. A search for anchimeric assistance J. Org. Chem. 1984, 49, 683-687
68. Truce, W. E.; Milionis, J. P. Friedel-Crafts cyclization of ω-phenylalkanesulfonyl chlorides J. Am. Chem. Soc. 1952, 74, 974-977
69. Papahatjis, D. P.; Nikas, S. P.; Kourouli, T.; Chari, R.; Xu, W.; Pertwee, R. G.; Makriyannis, A. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1′ J. Med. Chem. 2003, 46, 3221-3229
70. Prime; Schrödinger, LLC: New York, NY, 2012.
71. Mileni, M.; Kamtekar, S.; Wood, D. C.; Benson, T. E.; Cravatt, B. F.; Stevens, R. C. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation J. Mol. Biol. 2010, 400, 743-754